INNOVUS PHARMACEUTICALS, INC.: 10-Q filed 2014-05-14
What INNOVUS PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-05-14 (fiscal Q1 2014): 28 published measures, 52 facts as tagged in accession 0001144204-14-030375.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-05-14
- Fiscal period
- fiscal Q1 2014
- Accession
- 0001144204-14-030375 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INNOVUS PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 2,165,230 | USD | |
| At 2013-12-31 | 2,113,433 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 1,721,142 | USD | |
| At 2013-12-31 | 1,965,774 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 444,088 | USD | |
| At 2013-12-31 | 147,659 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 114,323 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -1,439,414 | USD | 90 |
| 2013-01-01 to 2013-03-31 | -337,349 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -248,304 | USD | 90 |
| 2013-01-01 to 2013-03-31 | -119,786 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 166,088 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 329,253 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 214,100 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 7,844,414 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 57,770 | USD | |
| At 2013-12-31 | 78,973 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 564,226 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 566,675 | USD | |
| At 2013-12-31 | 484,338 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 208,494 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 5,533 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 1,400,735 | USD | |
| At 2013-12-31 | 1,088,216 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 421,372 | USD | |
| At 2013-12-31 | 421,372 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 1,097,494 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 210,869 | USD | |
| At 2013-12-31 | 216,641 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,341,157 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 331,816 | USD | 90 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 208,166 | USD | |
| At 2013-12-31 | 177,851 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 110,237 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 55,567 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 23,695,499 | shares | |
| At 2013-12-31 | 21,548,456 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 8,264,806 | USD | |
| At 2013-12-31 | 6,531,110 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 1,097,494 | USD | |
| At 2013-12-31 | 1,106,831 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,285,590 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 331,816 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 21,203 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -5,772 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 30,315 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Inspect the source
- Entity
- INNOVUS PHARMACEUTICALS, INC. / CIK 0001411879
- Captured
- SEC response SHA-256
e77a101a672b8634c33f41442578c32e719835a043b28e20b379158f9e2f8bab
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001411879.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))